Extreme elevation of creatinine phosphokinase levels in neuroleptic malignant syndrome associated with atypical antipsychotics.
Ladds
Brian
B
Thomas
Pierre
P
Mejia
Carlina
C
Hauser
David
D
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000068180:Aripiprazole; D003024:Clozapine / Q000009:adverse effects* / Q000627:therapeutic use; D003402:Creatine Kinase / Q000097:blood*; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D006801:Humans; D008297:Male; D009203:Myocardial Infarction / Q000139:chemically induced / Q000201:enzymology; D009459:Neuroleptic Malignant Syndrome / Q000175:diagnosis / Q000201:enzymology*; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use; D015363:Quinolones / Q000009:adverse effects / Q000627:therapeutic use; D018967:Risperidone / Q000009:adverse effects / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy* / Q000201:enzymology; D014635:Valproic Acid / Q000009:adverse effects / Q000627:therapeutic use
D014150:Antipsychotic Agents; D010879:Piperazines; D015363:Quinolones; D014635:Valproic Acid; D000068180:Aripiprazole; D003402:Creatine Kinase; D003024:Clozapine; D018967:Risperidone